Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial

View ORCID ProfileHamed Hosseini, View ORCID ProfileAnahita Sadeghi, View ORCID ProfilePayam Tabarsi, View ORCID ProfileAzin Etemadimanesh, View ORCID ProfileIlad Alavi Darazam, View ORCID ProfileNasser Aghdami, View ORCID ProfileSaeed Kalantari, View ORCID ProfileMehrdad Hasibi, View ORCID ProfileAzar Hadadi, View ORCID ProfileFarhang Babamahmoodi, View ORCID ProfileMansooreh Momen-Heravi, View ORCID ProfileAhmad Hormati, View ORCID ProfileYunes Panahi, View ORCID ProfileRozita Khodashahi, View ORCID ProfileMohammadreza Salehi
doi: https://doi.org/10.1101/2021.08.13.21261992
Hamed Hosseini
1Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hamed Hosseini
Anahita Sadeghi
2Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anahita Sadeghi
Payam Tabarsi
3Department of Infectious Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Payam Tabarsi
Azin Etemadimanesh
4Department of Infectious Disease, Tehran University of Medical Science, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Azin Etemadimanesh
Ilad Alavi Darazam
3Department of Infectious Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ilad Alavi Darazam
Nasser Aghdami
4Department of Infectious Disease, Tehran University of Medical Science, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nasser Aghdami
Saeed Kalantari
5Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Saeed Kalantari
Mehrdad Hasibi
4Department of Infectious Disease, Tehran University of Medical Science, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mehrdad Hasibi
Azar Hadadi
4Department of Infectious Disease, Tehran University of Medical Science, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Azar Hadadi
Farhang Babamahmoodi
6Antimicrobial Resistance Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Farhang Babamahmoodi
Mansooreh Momen-Heravi
7Department of infectious diseases, faculty of medicine, Kashan university of medical sciences, Kashan, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mansooreh Momen-Heravi
Ahmad Hormati
8Gastroenterology and Hepatology Disease Research Center, Oom university of medical sciences, Iran
9Gastrointestinal and Liver Diseases Research Center, Iran university of medical sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ahmad Hormati
Yunes Panahi
10Pharmacotherapy Department, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yunes Panahi
Rozita Khodashahi
11Department of Infectious disease and tropical medicine, Faculty of Medicine, Mashhad university of medical sciences, Mashhad, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rozita Khodashahi
Mohammadreza Salehi
4Department of Infectious Disease, Tehran University of Medical Science, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mohammadreza Salehi
  • For correspondence: salehi.mohamad3@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction After emerging the global pandemic of SARS-CoV2 some preliminary studies demonstrated the efficacy of antiviral treatments. But shortly thereafter, inconsistencies in the results of further clinical trials raised doubts on the efficacy of these agents. In this study, we aimed to evaluate the effect of Remdesivir on hospitalized COVID-19 patients’ outcomes.

Material and methods This study was an open-label, single-armed, clinical trial on hospitalized patients diagnosed with COVID-19 who had progressive respiratory symptoms despite receiving standard care. All patients received Remdesivir and their characteristics, outcomes, time of treatment initiation, and respiratory support stages during hospitalization were registered and followed up for 14 days.

Results 145 patients with the mean age of 52.89 ± 1.12 years enrolled in this study, 38 (26.2%) died at the end of 14 days period. The mean time interval from the onset of the symptoms to antiviral treatment was 10.63±0.56 days. Thirty deceased patients (78.9%) were men, showing 2.8 times higher mortality chance compared to women (ORadj=2.77; 95%CI=1.08-7.09). The type of respiratory support on the first day of treatment initiation showed a significantly lower mortality chance in patients receiving O2 only than those who needed non-invasive and/or mechanical ventilation (ORadj=3.91; 95%CI=1.64-9.32). The start time (early vs late administration) and duration (less or more than 7 days) of antiviral treatment had no statistically significant association with mortality or ventilation escalation among the patients (p-value > 0.05).

Conclusion In this study, we showed that Remdesivir probably is not effective on the outcome of hospitalized COVID-19 patients.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

IRCT20200404046937N5

Clinical Protocols

https://www.irct.ir/trial/51178

Funding Statement

This study has been funded and supported by Tehran University of Medical Sciences (TUMS); Grant no. 99-1-97-47143.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval of this study was given by the ethics committee of Ahvaz University of Medical Sciences, Ahvaz, Khouzestan, Iran (Date of approval: 2020-09-22, ethics committee reference number of approval: IR.AJUMS.REC.1399.407)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Declaration of interests: Hereby, all authors of this study declare no conflict of interests before, during, and after the study was done.

Data Availability

All data are available by request contacting the corresponding author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted August 13, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial
Hamed Hosseini, Anahita Sadeghi, Payam Tabarsi, Azin Etemadimanesh, Ilad Alavi Darazam, Nasser Aghdami, Saeed Kalantari, Mehrdad Hasibi, Azar Hadadi, Farhang Babamahmoodi, Mansooreh Momen-Heravi, Ahmad Hormati, Yunes Panahi, Rozita Khodashahi, Mohammadreza Salehi
medRxiv 2021.08.13.21261992; doi: https://doi.org/10.1101/2021.08.13.21261992
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial
Hamed Hosseini, Anahita Sadeghi, Payam Tabarsi, Azin Etemadimanesh, Ilad Alavi Darazam, Nasser Aghdami, Saeed Kalantari, Mehrdad Hasibi, Azar Hadadi, Farhang Babamahmoodi, Mansooreh Momen-Heravi, Ahmad Hormati, Yunes Panahi, Rozita Khodashahi, Mohammadreza Salehi
medRxiv 2021.08.13.21261992; doi: https://doi.org/10.1101/2021.08.13.21261992

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12501)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (322)
  • Neurology (2785)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5342)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)